Proceedings of the Royal Society of Medicine and Fibromyalgia Action UK Webinar: Fibromyalgia in the 21st century: Redefining care. https://t.co/s02Ue47m6o https://t.co/FZYI7E8D3f

JAMA - Update/Review of Hemochromatosis Dx and Rx. - 5 gene defects in hepcidin. 95% HFE & the C282Y variant - 90%are asymptomatic - Suspicion w/ arthralgias, LFTs, hepatomegaly, cardiomyopathy, 1st degr relative - Untreated, 9% risk of cirrhosis https://t.co/CVDbXtqOBw https://t.co/R4ed2FNxdh

Study of 294 SLE pts on HCQ (2005-2021): 37 (13%) developed CHF w/ low EF (HFrEF), arrhythmia or cardiac death. After adjustments, wt-based dosing of HCQ not assoc w/ cardiac events(sHR 0.62; 0.41,0.92) & may decrease risk in non-smokers https://t.co/Qyp2odOfpj https://t.co/Q1qdv0CQ5P

Tyk2 Inhibition Effective in SLE Deucravacitinib, an oral, selective TYK2 inhibitor, has demonstrated efficacy in a phase II trial active systemic lupus erythematosus (SLE) patients. https://t.co/6pqRZO2VNA https://t.co/iJfhyRs8nw

Follow us on LinkedIn too! https://t.co/iylzzYRVAB https://t.co/7rKQShIzs5

New podcast available! Download where ever you get your podcasts and when can--rate, review and subscribe! Rheum Manpower Needs - More Programs https://t.co/W0mOCkyJbI https://t.co/USXTAtrE6U

The spicy topic of turmeric in RA Curcumin has increasingly been promoted as a potential RA therapy, but data presented at #ACR22 suggests it is unable to do any better than placebo in replacing conventional rheumatoid arthritis therapies. https://t.co/C0O0DyXn34 https://t.co/kv3dw476dT

Dual target blockade may be better than one in SLE Inhibition of B-cell Activating Factor (BAFF) has revolutionised the treatment of patients with systemic lupus erythematosus (SLE). https://t.co/uu6ygb4l8B https://t.co/nLO3oSiEVa

JAK inhibitors in rheumatic diseases Dr. Antoni Chan ( @synovialjoints) discusses abstracts 0510 and 0404 at #ACR22 https://t.co/7SSJITLrRT https://t.co/utjf8vlJof

AI Future of Sacroiliitis Assessment Dr. Rachel Tate ( @uptoTate) speaks with Dr. Fabian Proft about Abstract 0383 at #ACR22 Convergence. https://t.co/pfeW4iQBLq https://t.co/0lFx6CpWCx

Can I stop Methotrexate in RA? Dr. Pope and Dr. Meng discuss Abstract 0916 at #ACR22. https://t.co/0hK5kNHlrS https://t.co/AXJija7Yzo

Remibrutinib in Sjogren's Syndrome Dr. Putman reports on abstract 1113 presented at #ACR22 Convergence Abstract 1113: Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study https://t.co/ymFkNWPaXo https://t.co/0k6vLIu0Ku